Sevil Yasar1, Vijay R Varma2, Gregory C Harris3, Michelle C Carlson4. 1. Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. 2. National Institute on Aging, Intramural Research Program, Laboratory of Behavioral Neuroscience, Baltimore, MD, USA. 3. Way Station Inc., Columbia, MD, USA. 4. Department of Mental Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
BACKGROUND: Emerging evidence suggests a possible role of the renin angiotensin system in the pathophysiologic process of Alzheimer's disease, of which angiotensin converting enzyme-1 (ACE-1) and angiotensin II (ANGII) are important proteins. Few studies evaluated associations between blood ACE-1 and none between ANGII levels, and cognition. OBJECTIVE: Our pilot study was aimed to examine associations between blood ACE-1 and ANG II levels and cognitive function in non-demented participants at baseline and over a 1-year period. METHODS:56 participants were included from the Brain Health Substudy of the Baltimore Experience Corps Study. Linear regression analysis, adjusting for confounders, was used to determine associations between baseline ACE-1 and ANGII, and baseline and 1-year follow-up measures of psychomotor and processing speed, executive function, verbal learning memory and working memory, and whether these associations were mediated by blood pressure. RESULTS:Participants were predominantly female (75%), African-American (93%), with mean age of 67.8 years and education of 14.3 years. There were no associations between baseline ACE-1 or ANGII levels and cognitive function; however, there were significant association between baseline ACE-1 levels and 1-year follow-up Trail Making Test, Part A (β= 0.003, p = 0.04) and Digit Span (β= -0.001, p = 0.02). CONCLUSIONS: In this cognitively intact sample, elevated ACE-1 levels were associated with worse processing speed and working memory after 1 year. Findings from this pilot study suggest that changes in the RAS are associated with alterations in cognitive function warranting further assessment of the role of RAS in neurodegenerative disorders.
RCT Entities:
BACKGROUND: Emerging evidence suggests a possible role of the renin angiotensin system in the pathophysiologic process of Alzheimer's disease, of which angiotensin converting enzyme-1 (ACE-1) and angiotensin II (ANGII) are important proteins. Few studies evaluated associations between blood ACE-1 and none between ANGII levels, and cognition. OBJECTIVE: Our pilot study was aimed to examine associations between blood ACE-1 and ANG II levels and cognitive function in non-demented participants at baseline and over a 1-year period. METHODS: 56 participants were included from the Brain Health Substudy of the Baltimore Experience Corps Study. Linear regression analysis, adjusting for confounders, was used to determine associations between baseline ACE-1 and ANGII, and baseline and 1-year follow-up measures of psychomotor and processing speed, executive function, verbal learning memory and working memory, and whether these associations were mediated by blood pressure. RESULTS:Participants were predominantly female (75%), African-American (93%), with mean age of 67.8 years and education of 14.3 years. There were no associations between baseline ACE-1 or ANGII levels and cognitive function; however, there were significant association between baseline ACE-1 levels and 1-year follow-up Trail Making Test, Part A (β= 0.003, p = 0.04) and Digit Span (β= -0.001, p = 0.02). CONCLUSIONS: In this cognitively intact sample, elevated ACE-1 levels were associated with worse processing speed and working memory after 1 year. Findings from this pilot study suggest that changes in the RAS are associated with alterations in cognitive function warranting further assessment of the role of RAS in neurodegenerative disorders.
Entities:
Keywords:
Angiotensin II; angiotensin converting enzyme-1; cognition; cohort study
Authors: Jennifer S Rabin; Rodrigo D Perea; Rachel F Buckley; Taylor E Neal; Randy L Buckner; Keith A Johnson; Reisa A Sperling; Trey Hedden Journal: Cereb Cortex Date: 2019-03-01 Impact factor: 5.357
Authors: Ruth Peters; Nigel Beckett; Francoise Forette; Jaakko Tuomilehto; Robert Clarke; Craig Ritchie; Adam Waldman; Ivan Walton; Ruth Poulter; Shuping Ma; Marius Comsa; Lisa Burch; Astrid Fletcher; Christopher Bulpitt Journal: Lancet Neurol Date: 2008-07-07 Impact factor: 44.182
Authors: Sevil Yasar; Jin Xia; Wenliang Yao; Curt D Furberg; Qian-Li Xue; Carla I Mercado; Annette L Fitzpatrick; Linda P Fried; Claudia H Kawas; Kaycee M Sink; Jeff D Williamson; Steven T DeKosky; Michelle C Carlson Journal: Neurology Date: 2013-08-02 Impact factor: 9.910
Authors: Hans-Christoph Diener; Ralph L Sacco; Salim Yusuf; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon Journal: Lancet Neurol Date: 2008-08-29 Impact factor: 44.182
Authors: Vijay R Varma; Erwin J Tan; Alden L Gross; Greg Harris; William Romani; Linda P Fried; George W Rebok; Michelle C Carlson Journal: Am J Prev Med Date: 2015-09-02 Impact factor: 5.043
Authors: Caglar Cosarderelioglu; Lolita S Nidadavolu; Claudene J George; Ruth Marx-Rattner; Laura Powell; Qian-Li Xue; Jing Tian; Joy Salib; Esther S Oh; Luigi Ferrucci; Pervin Dincer; David A Bennett; Jeremy D Walston; Peter M Abadir Journal: J Gerontol A Biol Sci Med Sci Date: 2022-04-01 Impact factor: 6.591
Authors: João V Nani; Caroline Dal Mas; Camila M Yonamine; Vanessa K Ota; Cristiano Noto; Sintia I Belangero; Jair J Mari; Rodrigo Bressan; Quirino Cordeiro; Ary Gadelha; Mirian A F Hayashi Journal: Int J Neuropsychopharmacol Date: 2020-07-22 Impact factor: 5.176